drugset / Trial / NCT06126653
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
Phase 2
Completed
5 enrolled
Aardvark Therapeutics, Inc.
Center for Psychiatry And Behavioral Medicine Inc. · collab
RandomizedCrossoverDouble-blindTreatment
Summary
This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2025-01-13
- Completion
- 2025-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARD-501 | Unknown | 0.2 mg/kg | Oral |
| Subject | ARD-501 | Unknown | 0.5 mg/kg | Oral |